Infectious Diseases in Obstetrics and Gynecology / 2011 / Article / Tab 3

Clinical Study

Chlamydia trachomatis and Mycoplasma genitalium Plasma Antibodies in Relation to Epithelial Ovarian Tumors

Table 3

Prevalence of plasma antibodies in women with malignancies classified as type II tumors ( ) compared with matched controls and women with benign conditions.

Tumor group and antibodies analyzedAntibody-positive (%)Casesa versus matched controlsb, P valueAntibody-positive (%)Cases versus benign conditions, P value

Type II malignanciesCasesa ( )Matched controlsb ( )Cases Benign conditions ( )
 C. trachomatis IgG 8 (22%)23 (16%).4 8 (18%)51 (24%).4
 cHSP60 IgG10 (27%)29 (20%).412 (27%)48 (24%), c.6
 M. genitalium IgG 4 (11%) 5 (3%).08 4 (9%)17 (8%).8
Type II with prospective plasma samplesdCasesa ( )Matched controlsb ( )Cases ( )Benign conditions with prospective plasma samples ( )Cases versus benign conditions with prospective plasma sample, P valueCases versus all benign conditions, P value
 C. trachomatis IgG 2 (29%) 3 (11%).3 2 (29%) 4 (18%).6.7
 cHSP60 IgG 6 (86%) 5 (19%), c.002 6 (86%) 6 (30%), c.02.001
 M. genitalium IgG 0 0 0 2 (9%)1.01.0

aCases with matched controls available.
bFour controls per case from the NSHDS (Northern Sweden Health and Disease Study) were matched with respect to age and date of plasma-sampling.
cA few subjects had cHSP60 IgG antibody results that were indeterminant and therefore excluded from the statistical analyses. Assigning them extreme values (all positive or all negative) did not change the main outcomes.
dA subgroup of type II malignancies where plasma samples were drawn 1.3 to 5.1 years prior to diagnosis.
The Pearson chi-square was used first,and when the expected frequency was <5, Fisher’s exact test was used.